Gene Test Helps Heart Transplant Recipients
May 28th, 2010 | No Comments | Source: NEJM, Wall Street JournalRejection of the donor organ is a frequent and sometimes life-threatening complication of heart transplantation. It is best handled if caught early, and since early rejection is typically asymptomatic, physicians had heretofore been required to perform regular biopsies to screen for rejection of the transplanted heart.
The biopsy is expensive and not without risk however, so scientists have long searched for a non-invasive alternative to diagnose rejection.
That search may have yielded results. In a presentation at last month’s meeting of the International Society for Heart & Lung Transplantation, Michael Pham and colleagues from Stanford University showed that a genetic test reduced the need for biopsies in selected patients.
The gene test is known as Allomap. It is marketed by XDx and has been used on 7,000 transplant recipients so far. It costs about $3,000, or 25-40% less than the biopsy.
The study by Pham’s team included 602 transplant recipients. It showed that Allomap was as effective as routine biopsies in preventing serious episodes of transplant rejection like heart failure, the need for a re-transplant or death.
The study was limited to patients who were at low risk for rejection and had undergone the procedure at least 6 months prior to enrollment. Nineteen months after randomization, 14.5% of patients that were followed with the genetic test and 15.3% of those followed with routine biopsies suffered a major complication.
“You’re not going to harm patients by reducing the number of biopsies,” Pham told the Wall Street Journal.
Pham noted that his team’s findings could not be extrapolated to patients that had received a transplant within the last 6 months or to those at high risk for rejection.
The study appears in the New England Journal of Medicine.




The study appears in the
In that trial, Vytorin reduced LDL cholesterol levels much more than simvastatin alone but surprisingly, atherosclerotic plaques
A study by Mari Kitahata and colleagues may have settled the argument in favor of early drug treatment.
Valproate, available generically or under the brand name Depakote, is the
Since the heralded announcement in 2003, geneticists have undertaken hundreds of genomewide association studies designed to compare the DNA of healthy people with those of patients having specific diseases.
They also knew that human infants had a pretty good stock of these mitochondria-leaden cells, but they couldn’t find it in adults, and had assumed it disappeared as a byproduct of normal human development.
Some black adults had actually died of heart failure a decade before the chronic illness even began to affect whites.
Adding a skosh of reason to the endless cacophony emanating from Atkins advocates, Ornish impresarios and South Beach braggadocios, scientists at the Harvard School of Public Health have shown
The dieters recorded details of their food intake and tracked progress on a Web site.
The most successful dieters were those who regularly attended counseling sessions. They were good for a drop of 22 pounds on average.
Volpp’s team randomized 878 GE employees who smoked a pack-a-day into 2 groups.
Patients were followed for a median of 4 years.
To reach this conclusion, Wayne Ray and colleagues at Vanderbilt reviewed 







